{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T07:01:07Z","timestamp":1784876467308,"version":"3.55.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T00:00:00Z","timestamp":1780617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T00:00:00Z","timestamp":1784851200000},"content-version":"vor","delay-in-days":49,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Manipal Academy of Higher Education, Manipal"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      Hypervirulent\/Hypermucoviscous\n                      <jats:italic>Klebsiella pneumoniae<\/jats:italic>\n                      (HvKp\/HmKp) is associated with invasive community-acquired infections and metastatic complications, with reports of clinical failure despite in vitro susceptibility to standard antibiotics. Rifampicin has been described in experimental settings to modulate virulence by suppressing the hypermucoviscous phenotype through RNA polymerase-dependent regulation of capsule-associated genes. This scoping review aimed to systematically map the available evidence evaluating rifampicin as a potential antivirulence adjunct in HvKp\/HmKp infections.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      This scoping review was conducted in accordance with the Joanna Briggs Institute methodology and reported following the PRISMA-ScR guidelines. A structured search of PubMed\/MEDLINE, Embase, Scopus, and the Cochrane Library was performed from database inception to May 2026 using predefined terms related to hypervirulence,\n                      <jats:italic>Klebsiella pneumoniae<\/jats:italic>\n                      , and rifampicin\/rifampin. The search was supplemented by grey literature and reference list screening. Studies evaluating rifampicin in phenotypically, genotypically, or syndromically defined HvKp were eligible, including experimental and clinical reports describing rifampicin as adjunctive or salvage therapy. Data were charted and synthesized narratively to map study characteristics, proposed mechanisms, and reported outcomes.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Of 1,361 records identified, 11 studies met the inclusion criteria, comprising four experimental\/mechanistic studies, five full-text clinical case reports, and two conference abstracts. Experimental studies suggested that rifampicin may reduce hypermucoviscosity by suppressing capsule-associated pathways, particularly through the RpoB\u2013\n                      <jats:italic>rmpA<\/jats:italic>\n                      axis, leading to reduced capsule thickness and downregulation of virulence-related genes. Additional preclinical studies showed enhanced activity when rifampicin was used in combination with zidovudine or the outer membrane-disrupting peptide SLAP-S25, with improved bacterial killing and survival in murine infection models. Clinical evidence was limited to case reports and conference abstracts in which rifampicin was used only as part of combination therapy for severe, disseminated, persistent, or difficult-to-treat HvKp\/HmKp infections. Reported clinical outcomes were variable, and the independent contribution of rifampicin could not be determined.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Current evidence suggests that rifampicin has biologically plausible antivirulence activity against HvKp\/HmKp, mainly through suppression of capsule-associated hypermucoviscosity, and may have potential as an adjunct in selected severe or persistent infections. However, the available clinical evidence is sparse, uncontrolled, and heterogeneous. Rifampicin should therefore be considered hypothesis-generating rather than established therapy. Further mechanistic, pharmacokinetic, and prospective clinical studies are required to define its role, optimal combinations, dosing, safety, and clinical effectiveness in HvKp\/HmKp infections.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12879-026-13723-7","type":"journal-article","created":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T17:17:48Z","timestamp":1780679868000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Rifampicin as an antivirulence adjunct in hypervirulent\/hypermucoviscous Klebsiella pneumoniae infections: a scoping review"],"prefix":"10.1186","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5106-6200","authenticated-orcid":false,"given":"Danavath","family":"Nagendra","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asha K.","family":"Rajan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thejesh","family":"Srinivas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vandana","family":"K.E","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aruna","family":"Poojary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abduallah","family":"Zaawari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gagana","family":"Hanumaiah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neeraja","family":"R","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ancita","family":"Lobo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8392-2366","authenticated-orcid":false,"given":"Souvik","family":"Chaudhuri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,5]]},"reference":[{"key":"13723_CR1","doi-asserted-by":"publisher","first-page":"e00001","DOI":"10.1128\/CMR.00001-19","volume":"19","author":"TA Russo","year":"2019","unstructured":"Russo TA, Marr CM. Hypervirulent Klebsiella pneumoniae. Clin Microbiol Rev. 2019;19:32:e00001\u201319. https:\/\/doi.org\/10.1128\/CMR.00001-19.","journal-title":"Clin Microbiol Rev"},{"key":"13723_CR2","doi-asserted-by":"publisher","first-page":"4674","DOI":"10.1016\/j.radcr.2025.06.033","volume":"20","author":"D Nagendra","year":"2025","unstructured":"Nagendra D, Shanbhag RN, Eshwara V, Ramamoorthi VK, Priya K. Incidental detection of hypervirulent klebsiella pneumoniae liver abscess with systemic and cardiac complications in an elderly diabetic woman. Radiol Case Rep. 2025;20:4674\u20138. https:\/\/doi.org\/10.1016\/j.radcr.2025.06.033.","journal-title":"Radiol Case Rep"},{"key":"13723_CR3","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1111\/joim.13007","volume":"287","author":"JE Choby","year":"2020","unstructured":"Choby JE, Howard-Anderson J, Weiss DS. Hypervirulent Klebsiella pneumoniae - clinical and molecular perspectives. J Intern Med. 2020;287:283\u2013300. https:\/\/doi.org\/10.1111\/joim.13007.","journal-title":"J Intern Med"},{"issue":"5","key":"13723_CR4","doi-asserted-by":"publisher","first-page":"724","DOI":"10.3390\/ph18050724","volume":"18","author":"HF Hetta","year":"2025","unstructured":"Hetta HF, Alanazi FE, Ali MAS, et al. Hypervirulent Klebsiella pneumoniae: Insights into Virulence, Antibiotic Resistance, and Fight Strategies Against a Superbug. Pharmaceuticals (Basel). 2025;18(5):724. https:\/\/doi.org\/10.3390\/ph18050724. Published 2025 May 15.","journal-title":"Pharmaceuticals (Basel)"},{"key":"13723_CR5","doi-asserted-by":"publisher","unstructured":"Chen T, Ying L, Xiong L, Wang X, Lu P, Wang Y, et al. Understanding carbapenem-resistant hypervirulent Klebsiella pneumoniae: key virulence factors and evolutionary convergence. hLife 2024 1;2:611\u201324. https:\/\/doi.org\/10.1016\/j.hlife.2024.06.005.","DOI":"10.1016\/j.hlife.2024.06.005"},{"key":"13723_CR6","unstructured":"World Health Organization. Antimicrobial resistance, hypervirulent Klebsiella pneumoniae \u2013 global situation. Geneva: World Health Organization. 2024 Jul 31. Available from: https:\/\/www.who.int\/emergencies\/disease-outbreak-news\/item\/2024-DON527."},{"key":"13723_CR7","doi-asserted-by":"publisher","unstructured":"Nagendra D, Suresh V, Udupa AA, Srinivas T, Eshwara VK, Varma M, et al. Definitional ambiguity and the dual threat of hypervirulent Klebsiella pneumoniae infections: a systematic review and meta-analysis. Infect. 2025 10; https:\/\/doi.org\/10.1007\/s15010-025-02708-4.","DOI":"10.1007\/s15010-025-02708-4"},{"key":"13723_CR8","doi-asserted-by":"publisher","first-page":"370","DOI":"10.5005\/jp-journals-10071-24957","volume":"29","author":"D Nagendra","year":"2025","unstructured":"Nagendra D, Chaudhuri S, Gupta N, Shanbhag V, Eshwara VK, Rao S, et al. Prevalence, Risk Factors, and Clinical Outcomes of Hypervirulent Klebsiella pneumoniae Strains among Klebsiella pneumoniae Infections: A Systematic Review and Meta-analysis. Indian J Crit Care Med. 2025;29:370\u201393. https:\/\/doi.org\/10.5005\/jp-journals-10071-24957.","journal-title":"Indian J Crit Care Med"},{"key":"13723_CR9","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/S1473-3099(17)30489-9","volume":"18","author":"D Gu","year":"2018","unstructured":"Gu D, Dong N, Zheng Z, Lin D, Huang M, Wang L, et al. A fatal outbreak of ST11 carbapenem-resistant hypervirulent Klebsiella pneumoniae in a Chinese hospital: a molecular epidemiological study. Lancet Infect Dis. 2018;18:37\u201346. https:\/\/doi.org\/10.1016\/S1473-3099(17)30489-9.","journal-title":"Lancet Infect Dis"},{"key":"13723_CR10","doi-asserted-by":"publisher","unstructured":"Bhardwaj V, Annapandian VM, Sinazer AR, Alva A, Prasad S, Incidence. Risk factors and clinical outcomes of patients with Hypermucoviscoid Klebsiella in a tertiary intensive care unit. J Glob Infect Dis 2020 30;12:202\u20137. https:\/\/doi.org\/10.4103\/jgid.jgid_145_19.","DOI":"10.4103\/jgid.jgid_145_19"},{"key":"13723_CR11","doi-asserted-by":"publisher","first-page":"4532707","DOI":"10.1155\/2022\/4532707","volume":"2022","author":"V Vandhana","year":"2022","unstructured":"Vandhana V, Saralaya KV, Bhat S, Shenoy Mulki S, Bhat AK. Characterization of Hypervirulent Klebsiella pneumoniae (Hv-Kp): Correlation of Virulence with Antimicrobial Susceptibility. Int J Microbiol. 2022;2022:4532707. https:\/\/doi.org\/10.1155\/2022\/4532707.","journal-title":"Int J Microbiol"},{"issue":"1","key":"13723_CR12","doi-asserted-by":"publisher","first-page":"9719","DOI":"10.1038\/s41467-024-53930-x","volume":"15","author":"G Reszetnik","year":"2024","unstructured":"Reszetnik G, Hammond K, Mahshid S, et al. Next-generation rapid phenotypic antimicrobial susceptibility testing. Nat Commun. 2024;15(1):9719. https:\/\/doi.org\/10.1038\/s41467-024-53930-x. Published 2024 Nov 9.","journal-title":"Nat Commun"},{"key":"13723_CR13","doi-asserted-by":"publisher","first-page":"dlae069","DOI":"10.1093\/jacamr\/dlae069","volume":"6","author":"CK-F Lo","year":"2024","unstructured":"Lo CK-F, Sritharan A, Zhang J, Li N, Zhang C, Wang F, et al. Clinical significance of cefazolin inoculum effect in serious MSSA infections: a systematic review. JAC Antimicrob Resist. 2024;6:dlae069. https:\/\/doi.org\/10.1093\/jacamr\/dlae069.","journal-title":"JAC Antimicrob Resist"},{"key":"13723_CR14","doi-asserted-by":"publisher","first-page":"2825","DOI":"10.1093\/jac\/dkz226","volume":"74","author":"JR Lenhard","year":"2019","unstructured":"Lenhard JR, Bulman ZP. Inoculum effect of \u03b2-lactam antibiotics. J Antimicrob Chemother. 2019;74:2825\u201343. https:\/\/doi.org\/10.1093\/jac\/dkz226.","journal-title":"J Antimicrob Chemother"},{"key":"13723_CR15","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1093\/jac\/dkn554","volume":"63","author":"KI Udekwu","year":"2009","unstructured":"Udekwu KI, Parrish N, Ankomah P, Baquero F, Levin BR. Functional relationship between bacterial cell density and the efficacy of antibiotics. J Antimicrob Chemother. 2009;63:745\u201357. https:\/\/doi.org\/10.1093\/jac\/dkn554.","journal-title":"J Antimicrob Chemother"},{"key":"13723_CR16","doi-asserted-by":"publisher","unstructured":"Namikawa H, Oinuma K-I, Sakiyama A, Tsubouchi T, Tahara YO, Yamada K, et al. Discovery of anti-mucoviscous activity of rifampicin and its potential as a candidate antivirulence agent against hypervirulent Klebsiella pneumoniae. Int J Antimicrob Agents. 2019 1;54:167\u201375. https:\/\/doi.org\/10.1016\/j.ijantimicag.2019.05.018.","DOI":"10.1016\/j.ijantimicag.2019.05.018"},{"key":"13723_CR17","doi-asserted-by":"publisher","unstructured":"Xu C, Dong N, Chen K, Yang X, Zeng P, Hou C, et al. Bactericidal, anti-biofilm, and anti-virulence activity of vitamin C against carbapenem-resistant hypervirulent Klebsiella pneumoniae. iScience 2022 18;25:103894. https:\/\/doi.org\/10.1016\/j.isci.2022.103894.","DOI":"10.1016\/j.isci.2022.103894"},{"key":"13723_CR18","doi-asserted-by":"publisher","first-page":"136","DOI":"10.18683\/germs.2024.1426","volume":"14","author":"J Wangkheimayum","year":"2024","unstructured":"Wangkheimayum J, Banerjee T, Baishya S, Sharma S, Choudhury MD, Laskar MA, et al. Linoleic acid acts as a potential anti-virulence agent in Klebsiella pneumoniae. Germs. 2024;14:136\u201348. https:\/\/doi.org\/10.18683\/germs.2024.1426.","journal-title":"Germs"},{"key":"13723_CR19","doi-asserted-by":"publisher","first-page":"e1012787","DOI":"10.1371\/journal.ppat.1012787","volume":"621","author":"T Wang","year":"2025","unstructured":"Wang T, Yang H, Sheng Q, Ding Y, Zhang J, Chen F, et al. Isoferulic acid facilitates effective clearance of hypervirulent Klebsiella pneumoniae through targeting capsule. PLoS Pathog. 2025;621:e1012787. https:\/\/doi.org\/10.1371\/journal.ppat.1012787.","journal-title":"PLoS Pathog"},{"key":"13723_CR20","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.jgar.2022.11.018","volume":"32","author":"M Tohda","year":"2023","unstructured":"Tohda M, Oinuma K-I, Sakiyama A, Tsubouchi T, Niki M, Namikawa H, et al. Rifampicin exerts anti-mucoviscous activity against hypervirulent Klebsiella pneumoniae via binding to the RNA polymerase \u03b2-subunit. J Glob Antimicrob Resist. 2023;32:21\u20138. https:\/\/doi.org\/10.1016\/j.jgar.2022.11.018.","journal-title":"J Glob Antimicrob Resist"},{"key":"13723_CR21","doi-asserted-by":"publisher","unstructured":"Campbell EA, Korzheva N, Mustaev A, Murakami K, Nair S, Goldfarb A, et al. Structural mechanism for rifampicin inhibition of bacterial RNA polymerase. Cell. 2001 23;104:901\u201312. https:\/\/doi.org\/10.1016\/s0092-86740100286-0.","DOI":"10.1016\/s0092-86740100286-0"},{"key":"13723_CR22","doi-asserted-by":"publisher","first-page":"2091","DOI":"10.1128\/AAC.05792-11","volume":"56","author":"W Smythe","year":"2012","unstructured":"Smythe W, Khandelwal A, Merle C, Rustomjee R, Gninafon M, Bocar Lo M, et al. A semimechanistic pharmacokinetic-enzyme turnover model for rifampin autoinduction in adult tuberculosis patients. Antimicrob Agents Chemother. 2012;56:2091\u20138. https:\/\/doi.org\/10.1128\/AAC.05792-11.","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"13723_CR23","doi-asserted-by":"publisher","first-page":"e01746","DOI":"10.1128\/AAC.01746-18","volume":"63","author":"W Zimmerli","year":"2019","unstructured":"Zimmerli W, Sendi P. Role of Rifampin against Staphylococcal Biofilm Infections In Vitro, in Animal Models, and in Orthopedic-Device-Related Infections. Antimicrob Agents Chemother. 2019;63(2):e01746\u201318. https:\/\/doi.org\/10.1128\/AAC.01746-18. Published 2019 Jan 29.","journal-title":"Antimicrob Agents Chemother"},{"key":"13723_CR24","doi-asserted-by":"publisher","unstructured":"Kawaguchi Y, Tada K, Shibata R, Ishii H, Ito N, Igawa T. A case of emphysematous pyelonephritis caused by the hypermucoviscosity phenotype of Klebsiella pneumoniae . Urol Case Rep. 2022 30;46:102290. https:\/\/doi.org\/10.1016\/j.eucr.2022.102290.","DOI":"10.1016\/j.eucr.2022.102290"},{"key":"13723_CR25","doi-asserted-by":"publisher","first-page":"e01276","DOI":"10.1016\/j.idcr.2021.e01276","volume":"26","author":"Y-C Lin","year":"2021","unstructured":"Lin Y-C, Cao X, Mo Y-C, Xie C-P, Zhang Y-F, Li N, et al. Successful treatment of hypervirulent Klebsiella pneumoniae bacteremia with combination carbapenem and rifampicin. IDCases. 2021;26:e01276. https:\/\/doi.org\/10.1016\/j.idcr.2021.e01276.","journal-title":"IDCases"},{"key":"13723_CR26","doi-asserted-by":"publisher","first-page":"e67985","DOI":"10.7759\/cureus.67985","volume":"16","author":"H Hamada","year":"2024","unstructured":"Hamada H, Hayashi K, Morikawa Y, Hayashi M, Shirasaki A, Yamamoto C. Iliopsoas Abscess, Spondylodiscitis, Septic Pulmonary Embolism, and Symmetrical Peripheral Gangrene by Hypermucoviscous Klebsiella pneumoniae. Cureus. 2024;16:e67985. https:\/\/doi.org\/10.7759\/cureus.67985.","journal-title":"Cureus"},{"key":"13723_CR27","doi-asserted-by":"publisher","first-page":"e70108","DOI":"10.1002\/ccr3.70108","volume":"13","author":"A Joshi","year":"2025","unstructured":"Joshi A, Wari E, Ghnaima H, Nader G, Chennupati S, Jafar N. Invasive Liver Abscess Syndrome in the Immunocompromised: A Case Report. Clin Case Rep. 2025;13:e70108. https:\/\/doi.org\/10.1002\/ccr3.70108.","journal-title":"Clin Case Rep"},{"key":"13723_CR28","doi-asserted-by":"publisher","unstructured":"ESCMID Global Abstract Book 2024. CMI Communications. 2024 1;1:100013. https:\/\/doi.org\/10.1016\/j.cmicom.2024.100013.","DOI":"10.1016\/j.cmicom.2024.100013"},{"key":"13723_CR29","doi-asserted-by":"publisher","unstructured":"Aromataris E, Lockwood C, Porritt K, Pilla B, Jordan Z, editors. JBI Manual for Evidence Synthesis. Adelaide: JBI; 2024 [cited 2026 May 14]. Available from: https:\/\/synthesismanual.jbi.global. https:\/\/doi.org\/10.46658\/JBIMES-24-01.","DOI":"10.46658\/JBIMES-24-01"},{"key":"13723_CR30","unstructured":"Nagendra D, Rajan A, Chaudhuri S. Managing refractory hypervirulent Klebsiella pneumoniae infections with rifampicin as salvage therapy: a scoping review. OSF; 2025. Available from: https:\/\/osf.io\/z5bmg."},{"key":"13723_CR31","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1016\/j.jinf.2022.05.004","volume":"85","author":"H Ni","year":"2022","unstructured":"Ni H, Chan K-WB, Cheng Q, Chen K, Xie M, Wang H, et al. A novel clinical therapy to combat infections caused by Hypervirulent Carbapenem-Resistant Klebsiella pneumoniae. J Infect. 2022;85:174\u2013211. https:\/\/doi.org\/10.1016\/j.jinf.2022.05.004.","journal-title":"J Infect"},{"issue":"1","key":"13723_CR32","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1093\/jac\/dkac387","volume":"78","author":"Z Yang","year":"2022","unstructured":"Yang Z, Song M, Li X, Zhang Q, Shen J, Zhu K. Synergy of outer membrane disruptor SLAP-S25 with hydrophobic antibiotics against Gram-negative pathogens. J Antimicrob Chemother. 2022;78(1):263\u201371. https:\/\/doi.org\/10.1093\/jac\/dkac387.","journal-title":"J Antimicrob Chemother"},{"issue":"1","key":"13723_CR33","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1186\/s12879-024-09762-7","volume":"24","author":"S Sokhanvari","year":"2024","unstructured":"Sokhanvari S, Bagheri A, Badmasti F, Solgi H. Molecular characterization of NDM and OXA-48-like-producing Klebsiella pneumoniae ST16 and hypervirulent ST337 clone among two patients; a case report. BMC Infect Dis. 2024;24(1):850. https:\/\/doi.org\/10.1186\/s12879-024-09762-7. Published 2024 Aug 22.","journal-title":"BMC Infect Dis"},{"issue":"4 Suppl","key":"13723_CR34","doi-asserted-by":"publisher","first-page":"A753","DOI":"10.1016\/j.chest.2022.08.593","volume":"162","author":"S Mitchell","year":"2022","unstructured":"Mitchell S, Kooken BW, Taylor BT. Klebsiella pneumoniae: a common bacteria becoming a hypervirulent syndrome. Chest. 2022;162(4 Suppl):A753. https:\/\/doi.org\/10.1016\/j.chest.2022.08.593.","journal-title":"Chest"},{"key":"13723_CR35","doi-asserted-by":"publisher","first-page":"107254","DOI":"10.1016\/j.phrs.2024.107254","volume":"206","author":"H Ni","year":"2024","unstructured":"Ni H, Chan BK, Ye L, et al. Lowering mortality risk in CR-HvKP infection in intestinal immunohistological and microbiota restoration. Pharmacol Res. 2024;206:107254. https:\/\/doi.org\/10.1016\/j.phrs.2024.107254.","journal-title":"Pharmacol Res"},{"issue":"3","key":"13723_CR36","doi-asserted-by":"publisher","first-page":"273","DOI":"10.20524\/aog.2018.0250","volume":"31","author":"T Ladopoulos","year":"2018","unstructured":"Ladopoulos T, Giannaki M, Alexopoulou C, Proklou A, Pediaditis E, Kondili E. Gastrointestinal dysmotility in critically ill patients. Ann Gastroenterol. 2018;31(3):273\u201381. https:\/\/doi.org\/10.20524\/aog.2018.0250.","journal-title":"Ann Gastroenterol"},{"key":"13723_CR37","doi-asserted-by":"publisher","first-page":"e00776","DOI":"10.1128\/JCM.00776-18","volume":"56","author":"TA Russo","year":"2018","unstructured":"Russo TA, Olson R, Fang C-T, Stoesser N, Miller M, MacDonald U, et al. Identification of biomarkers for differentiation of hypervirulent Klebsiella pneumoniae from classical K. pneumoniae. J Clin Microbiol. 2018;56:e00776\u201318. https:\/\/doi.org\/10.1128\/JCM.00776-18.","journal-title":"J Clin Microbiol"},{"key":"13723_CR38","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1016\/j.cmi.2021.11.025","volume":"28","author":"M Paul","year":"2022","unstructured":"Paul M, Carrara E, Retamar P, T\u00e4ngd\u00e9n T, Bitterman R, Bonomo RA, et al. European Society of Clinical Microbiology and Infectious Diseases (ESCMID) guidelines for the treatment of infections caused by multidrug-resistant Gram-negative bacilli (endorsed by European society of intensive care medicine). Clin Microbiol Infect. 2022;28:521\u201347. https:\/\/doi.org\/10.1016\/j.cmi.2021.11.025.","journal-title":"Clin Microbiol Infect"},{"key":"13723_CR39","doi-asserted-by":"publisher","first-page":"3990","DOI":"10.1128\/AAC.00179-13","volume":"57","author":"C Tascini","year":"2013","unstructured":"Tascini C, Tagliaferri E, Giani T, Leonildi A, Flammini S, Casini B, et al. Synergistic activity of colistin plus rifampin against colistin-resistant KPC-producing Klebsiella pneumoniae. Antimicrob Agents Chemother. 2013;57:3990\u20133. https:\/\/doi.org\/10.1128\/AAC.00179-13.","journal-title":"Antimicrob Agents Chemother"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-026-13723-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-026-13723-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-026-13723-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T06:12:52Z","timestamp":1784873572000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12879-026-13723-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,5]]},"references-count":39,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["13723"],"URL":"https:\/\/doi.org\/10.1186\/s12879-026-13723-7","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,5]]},"assertion":[{"value":"31 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"1392"}}